• 1
    Armistead P, de Lima M, Pierce S, et al. Quantifying the survival benefit for allogeneic stem cell transplant in relapsed acute myeloid leukemia. Biol Blood Marrow Transplant. 2009; 15: 1431-1438.
  • 2
    Thomas ED, Buckner CD, Banaji M, et al. One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood. 1977; 49: 511-533.
  • 3
    Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009; 10: 223-232.
  • 4
    Issa JP, Garcia-Manero G, Giles FJ, et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies. Blood. 2004; 103: 1635-1640.
  • 5
    de Lima M, Ravandi F, Shahjahan M, et al. Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias. Cancer. 2003; 97: 1242-1247.
  • 6
    Pinto A, Maio M, Attadia V, Zappacosta S, Cimino R. Modulation of HLA-DR antigens expression in human myeloid leukaemia cells by cytarabine and 5-aza-2′-deoxycytidine. Lancet. 1984; 2: 867-868.
  • 7
    Pinto A, Attadia V, Fusco A, Ferrara F, Spada OA, Di Fiore PP. 5-Aza-2′-deoxycytidine induces terminal differentiation of leukemic blasts from patients with acute myeloid leukemias. Blood. 1984; 64: 922-929.
  • 8
    Coral S, Sigalotti L, Covre A, Nicolay HJ, Natali PG, Maio M. 5-AZA-2′-deoxycytidine in cancer immunotherapy: a mouse to man story. Cancer Res. 2007; 67: 2900-2901.
  • 9
    Saunthararajah Y. Decitabine and sickle cell disease: molecular therapy for a molecular disease. Pediatr Hematol Oncol. 2007; 24: 465-468.
  • 10
    Jabbour E, Giralt S, Kantarjian H, et al. Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia. Cancer. 2009; 115: 1899-1905.
  • 11
    Greenberg P, Cox C, LeBeau M, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997; 89: 2079-2088.
  • 12
    Parmar S, de Lima M, Zou Y, et al. Donor-recipient mismatches in MHC class I chain-related gene A in unrelated donor transplantation lead to increased incidence of acute graft-versus-host disease. Blood. 2009; 114: 2884-2887.
  • 13
    de Lima M, Champlin RE, Thall PF, et al. Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome. Leukemia. 2008; 22: 258-264.
  • 14
    Soriano AO, Yang H, Faderl S, et al. Safety and clinical activity of the combination of 5-azacytidine, valproic acid and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood. 2007; 110: 2303-2308.
  • 15
    Braun TM, Thall PF, Nguyen H, de Lima M. Simultaneously optimizing dose and schedule of a new cytotoxic agent. Clin Trials. 2007; 4: 113-124.
  • 16
    O'Quigley J, Pepe M, Fisher L. Continual reassessment method: a practical design for phase I clinical trials in cancer. Biometrics. 1990; 46: 33-48.
  • 17
    Kaplan M, Meier P. Nonparametric estimator from incomplete observations. J Am Statistical Assoc. 1958; 53: 457-481.
  • 18
    Mantel N. Evaluation of survival data and 2 new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966; 50:163-170.
  • 19
    Johnson V. A Bayesian X2 test for goodness-of-fit. Ann Stat. 2004; 32: 2361-2384.
  • 20
    WinBugs. WinBugs Version 1.4. London, UK: Imperial College & Medical Research Council, UK; 2009.
  • 21
    Venables WN, Ripley BD. Modern Applied Statistics With Splus. 4th ed. New York, NY: Springer; 2002.
  • 22
    Oran B, Giralt S, Couriel D, et al. Treatment of AML and MDS relapsing after reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation. Leukemia. 2007; 21: 2540-2544.
  • 23
    Arfons LM, Tomblyn M, Rocha V, Lazarus HM. Second hematopoietic stem cell transplantation in myeloid malignancies. Curr Opin Hematol. 2009; 16: 112-123.
  • 24
    Shaw BE, Russell NH. Treatment options for the management of acute leukaemia relapsing following an allogeneic transplant. Bone Marrow Transplant. 2008; 41: 495-503.
  • 25
    Mielcarek M, Storer BE, Flowers ME, Storb R, Sandmaier BM, Martin PJ. Outcomes among patients with recurrent high-risk hematologic malignancies after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2007; 13: 1160-1168.
  • 26
    Mortimer J, Blinder MA, Schulman S, et al. Relapse of acute leukemia after marrow transplantation: natural history and results of subsequent therapy. J Clin Oncol. 1989; 7: 50-57.
  • 27
    Lubbert M, Bertz H, Wasch R, et al. Efficacy of a 3-day, low-dose treatment with 5-azacytidine followed by donor lymphocyte infusions in older patients with acute myeloid leukemia or chronic myelomonocytic leukemia relapsed after allografting. Bone Marrow Transplant. 2010; 45: 627-632.
  • 28
    Figueroa ME, Skrabanek L, Li Y, et al. MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood. 2009; 114: 3448-3458.
  • 29
    Stankovic T, McLarnon A, Agathanggelou A, Goodyear O, Craddock C, Moss P. Epigenetic manipulation of cancer testis antigen (CTAg) expression: a strategy for manipulating the graft-versus leukaemia response in patients allografted for haematological malignancies [abstract]. Blood. 2008; 112: 600a.
  • 30
    Campoli S, Ferrone S. HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance. Oncogene. 2008; 27: 5869-5885.
  • 31
    Hambach L, Ling KW, Pool J, et al. Hypomethylating drugs convert HA-1-negative solid tumors into targets for stem cell-based immunotherapy. Blood. 2009; 113: 2715-2722.
  • 32
    Sanchez-Abarca LI, Gutierrez-Cosio S, Santamaria C, et al. Immunomodulatory effect of 5-azacytidine (5-azaC): potential role in the transplantation setting. Blood. 2010; 115: 107-121.
  • 33
    Schmid C, Schleuning M, Ledderose G, Tischer J, Kolb H. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor-lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol. 2005; 23: 5675-5687.
  • 34
    Wong R, Shahjahan M, Wang X, et al. Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation. Biol Blood Marrow Transplant. 2005; 11: 108-114.
  • 35
    Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002; 100: 4325-4336.
  • 36
    Sorror ML, Giralt S, Sandmaier BM, et al. Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. Blood. 2007; 110: 4606-4613.